Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane
Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane Henney announced Burlingtons departure in January (SCAN 2/3/99) and appointed Jacobson as his temporary successor last month. Henney continues to seek a permanent replacement for the position.
Jacobson arrived at the FDAs Bureau of Radiological Health in 1975 as a research geneticist. She has held several scientific and management posts at the Bureau and the CDRH, including director of the Office of Science and Technology and deputy director for science at the CDRH. Jacobson has served as acting director at the CDRH once before, from December 1992 to February 1993.
Jacobson will begin her tenure as acting director on March 13, when Burlington leaves for a new post as head of regulatory affairs at Wyeth-Ayerst Pharmaceuticals in Philadelphia.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.